Cellular mechanisms of multiple myeloma bone disease

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Oranger, Angela ^a   Carbone, Claudia ^a   Izzo, Maddalena ^a   Grano, Maria ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 165; BHQ 880; DENOSUMAB; LY 212399; MLN 3897; SOTATERCEPT; TABALUMAB; UNCLASSIFIED DRUG; CYTOKINE; NEUTRALIZING ANTIBODY; TUMOR PROTEIN;

ARTICLE; BONE CELL; BONE DISEASE; BONE REMODELING; CELL ACTIVITY; CELL PROLIFERATION; CYTOKINE PRODUCTION; DENDRITIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOCOMPETENT CELL; MULTIPLE MYELOMA; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; PATHOGENESIS; PLASMA CELL; PRIORITY JOURNAL; STROMA CELL; T LYMPHOCYTE; BIOSYNTHESIS; BONE; CELL DIFFERENTIATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; IMMUNOLOGY; LYMPHOCYTE; PATHOLOGY; REVIEW; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS;

ANTIBODIES, NEUTRALIZING; BONE AND BONES; BONE REMODELING; CELL DIFFERENTIATION; CELLULAR MICROENVIRONMENT; CYTOKINES; HUMANS; LYMPHOCYTES; MULTIPLE MYELOMA; NEOPLASM PROTEINS; OSTEOBLASTS; OSTEOCLASTS; OSTEOLYSIS; PLASMA CELLS; STROMAL CELLS;

EID: 84879309487     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/289458     Document Type: Article

References (127)

1. Kyle R. A., Rajkumar S. V., Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009 23 1 3 9 2-s2.0-58249097191 10.1038/leu.2008.291
2. Landgren O., Kyle R. A., Pfeiffer R. M., Katzmann J. A., Caporaso N. E., Hayes R. B., Dispenzieri A., Kumar S., Clark R. J., Baris D., Hoover R., Rajkumar S. V., Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009 113 22 5412 5417 2-s2.0-67049162188 10.1182/blood-2008-12-194241
3. Weiss B. M., Abadie J., Verma P., Howard R. S., Kuehl W. M., A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009 113 22 5418 5422 2-s2.0-67049114114 10.1182/blood-2008-12-195008
4. Kyle R. A., Kumar S., The significance of monoclonal gammopathy of undetermined significance. Haematologica 2009 94 12 1641 1644 2-s2.0-73149115752 10.3324/haematol.2009.013961
5. Kyle R. A., Rajkumar S. V., Multiple myeloma. The New England Journal of Medicine 2004 351 18 1860 1873 2-s2.0-6944235003
6. Saad F., Lipton A., Cook R., Chen Y., Smith M., Coleman R., Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007 110 8 1860 1867 2-s2.0-35048875471 10.1002/cncr.22991
7. Sonmez M., Akagun T., Topbas M., Cobanoglu U., Sonmez B., Yilmaz M., Ovali E., Omay S. B., Effect of pathologic fractures on survival in multiple myeloma patients: a case control study. Journal of Experimental and Clinical Cancer Research 2008 27 1, article 11 2-s2.0-52949131560 10.1186/1756-9966-27-11
8. Björkstrand B., Iacobelli S., Hegenbart U., Gruber A., Greinix H., Volin L., Narni F., Musto P., Beksac M., Bosi A., Milone G., Corradini P., Goldschmidt H., De Witte T., Morris C., Niederwieser D., Gahrton G., Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. Journal of Clinical Oncology 2011 29 22 3016 3022 2-s2.0-80051642093 10.1200/JCO.2010.32. 7312
9. Cook G., Campbell J. D. M., Immune regulation in multiple myeloma: the host-tumour conflict. Blood Reviews 1999 13 3 151 162 2-s2.0-0032873880 10.1054/blre.1999.0111
10. Gupta G. P., Massagué J., Cancer metastasis: building a framework. Cell 2006 127 4 679 695 2-s2.0-33751252276 10.1016/j.cell.2006.11.001
11. Amé-Thomas P., Hajjami H. M., Monvoisin C., Jean R., Monnier D., Caulet-Maugendre S., Guillaudeux T., Lamy T., Fest T., Tarte K., Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood 2007 109 2 693 702 2-s2.0-33846255324 10.1182/blood-2006-05-020800
12. Hideshima T., Mitsiades C., Tonon G., Richardson P. G., Anderson K. C., Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nature Reviews Cancer 2007 7 8 585 598 2-s2.0-34547106018 10.1038/nrc2189
13. Chauhan D., Uchiyama H., Akbarali Y., Urashima M., Yamamoto K., Libermann T. A., Anderson K. C., Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF- B. Blood 1996 87 3 1104 1112 2-s2.0-0030041147
14. Roodman G. D., Mechanisms of bone metastasis. The New England Journal of Medicine 2004 350 16 1655 1664 2-s2.0-4644261592 10.1056/NEJMra030831
15. Giuliani N., Rizzoli V., Roodman G. D., Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 2006 108 13 3992 3996 2-s2.0-33751193178 10.1182/blood-2006-05-026112
16. Bataille R., Chappard D., Marcelli C., Dessauw P., Sany J., Baldet P., Alexandre C., Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. Journal of Clinical Oncology 1989 7 12 1909 1914 2-s2.0-0024786736
17. Yang C. R., Wang J. H., Hsieh S. L., Wang S. M., Hsu T. L., Lin W. W., Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells. Cell Death and Differentiation 2004 11 1 S97 S107 2-s2.0-4344605748 10.1038/sj.cdd.4401403
18. Brunetti G., Oranger A., Mori G., Centonze M., Colaianni G., Rizzi R., Liso V., Zallone A., Grano M., Colucci S., The formation of osteoclasts in multiple myeloma bone disease patients involves the secretion of soluble decoy receptor 3. Annals of the New York Academy of Sciences 2010 1192 298 302 2-s2.0-77950641605 10.1111/j.1749-6632.2009.05304.x
19. Colucci S., Brunetti G., Mori G., Oranger A., Centonze M., Mori C., Cantatore F. P., Tamma R., Rizzi R., Liso V., Zallone A., Grano M., Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients. Leukemia 2009 23 11 2139 2146 2-s2.0-70450240910 10.1038/leu.2009.136
20. Lee J. W., Chung H. Y., Ehrlich L. A., Jelinek D. F., Callander N. S., Roodman G. D., Choi S. J., IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 2004 103 6 2308 2315 2-s2.0-1542313900 10.1182/blood-2003-06-1992
21. Barton B. E., Mayer R., IL-3 induces differentiation of bone marrow precursor cells to osteoclast-like cells. Journal of Immunology 1989 143 10 3211 3216 2-s2.0-0024326940
22. Ehrlich L. A., Chung H. Y., Ghobrial I., Choi S. J., Morandi F., Colla S., Rizzoli V., Roodman G. D., Giuliani N., EL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood 2005 106 4 1407 1414 2-s2.0-23744507989 10.1182/blood-2005-03-1080
23. Merico F., Bergui L., Gregoretti M. G., Ghia P., Aimo G., Lindley I. J. D., Cytokines involved in the progression of multiple myeloma. Clinical and Experimental Immunology 1993 92 1 27 31 2-s2.0-0027405780
24. Uneda S., Hata H., Matsuno F., Harada N., Mitsuya Y., Kawano F., Mitsuya H., Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. British Journal of Haematology 2003 120 1 53 55 2-s2.0-0037219741 10.1046/j.1365-2141.2003.04040.x
25. Man J. H., Choi S. J., Kurihara N., Koide M., Oba Y., Roodman G. D., Macrophage inflammatory protein-1 α is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor B ligand. Blood 2001 97 11 3349 3353 2-s2.0-0035383761 10.1182/blood.V97.11.3349
26. Abe M., Hiura K., Wilde J., Moriyama K., Hashimoto T., Ozaki S., Wakatsuki S., Kosaka M., Kido S., Inoue D., Matsumoto T., Role for macrophage inflammatory protein (MIP)-1 α and MIP-1 β in the development of osteolytic lesions in multiple myeloma. Blood 2002 100 6 2195 2202 2-s2.0-0037105599
27. Choi S. J., Cruz J. C., Craig F., Chung H., Devlin R. D., Roodman G. D., Alsina M., Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000 96 2 671 675 2-s2.0-0342322717
28. Wolpe S. D., Davatelis G., Sherry B., Beutler B., Hesse D. G., Nguyen H. T., Moldawer L. L., Nathan C. F., Lowry S. F., Cerami A., Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. Journal of Experimental Medicine 1988 167 2 570 581 2-s2.0-0023841073
29. Kukita T., Nomiyama H., Ohmoto Y., Kukita A., Shuto T., Hotokebuchi T., Sugioka Y., Miura R., Iijima T., Macrophage inflammatory protein-1 α (LD78) expressed in human bone marrow: iIts role in regulation of hematopoiesis and osteoclast recruitment. Laboratory Investigation 1997 76 3 399 406 2-s2.0-0030903039
30. Scheven B. A. A., Milne J. S., Hunter I., Robins S. P., Macrophage-inflammatory protein-1 α regulates preosteoclast differentiation in vitro. Biochemical and Biophysical Research Communications 1999 254 3 773 778 2-s2.0-0033608227 10.1006/bbrc.1998.9909
31. Rivollier A., Mazzorana M., Tebib J., Piperno M., Aitsiselmi T., Rabourdin-Combe C., Jurdic P., Servet-Delprat C., Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 2004 104 13 4029 4037 2-s2.0-10244259169 10.1182/blood-2004-01-0041
32. Lentzsch S., Gries M., Janz M., Bargou R., Dörken B., Mapara M. Y., Macrophage inflammatory protein 1-alpha (MIP-1 α) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 2003 101 9 3568 3573 2-s2.0-0038386032 10.1182/blood-2002-08-2383
33. Choi S. J., Oba Y., Gazitt Y., Alsina M., Cruz J., Anderson J., David Roodman G., Antisense inhibition of macrophage inflammatory protein 1- α blocks bone destruction in a model of myeloma bone disease. Journal of Clinical Investigation 2001 108 12 1833 1841 2-s2.0-0035664488 10.1172/JCI200113116
34. Oyajobi B. O., Franchin G., Williams P. J., Pulkrabek D., Gupta A., Munoz S., Grubbs B., Zhao M., Chen D., Sherry B., Mundy G. R., Dual effects of macrophage inflammatory protein-1 α on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 2003 102 1 311 319 2-s2.0-0038579121 10.1182/blood-2002-12-3905
35. Vallet S., Raje N., Ishitsuka K., Hideshima T., Podar K., Chhetri S., Pozzi S., Breitkreutz I., Kiziltepe T., Yasui H., Ocio E. M., Shiraishi N., Jin J., Okawa Y., Ikeda H., Mukherjee S., Vaghela N., Cirstea D., Ladetto M., Boccadoro M., Anderson K. C., MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood 2007 110 10 3744 3752 2-s2.0-36348988548 10.1182/blood-2007- 05-093294
36. Roodman G. D., Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer 1997 80 8 1557 1563 2-s2.0-0030791806
37. Lacey D. L., Tan H. L., Lu J., Kaufman S., Van G., Qiu W., Rattan A., Scully S., Fletcher F., Juan T., Kelley M., Burgess T. L., Boyle W. J., Polverino A. J., Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. The American Journal of Pathology 2000 157 2 435 448 2-s2.0-0033888977
38. Lacey D. L., Timms E., Tan H. L., Kelley M. J., Dunstan C. R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.-., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., Boyle W. J., Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998 93 2 165 176 2-s2.0-0032540319 10.1016/S0092-8674(00)81569-X
39. Grano M., Brunetti G., Colucci S., Immunomodulation of multiple myeloma bone disease. Clinical Reviews in Bone and Mineral Metabolism 2009 7 4 293 300 2-s2.0-70449521102 10.1007/s12018-009-9058-2
40. Heider U., Langelotz C., Jakob C., Zavrski I., Fleissner C., Eucker J., Possinger K., Hofbauer L. C., Sezer O., Expression of receptor activator of nuclear factor B ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clinical Cancer Research 2003 9 4 1436 1440 2-s2.0-0037389602
41. Sezer O., Heider U., Jakob C., Eucker J., Possinger K., Human bone marrow myeloma cells express RANKL. Journal of Clinical Oncology 2002 20 1 353 354 2-s2.0-0036140071
42. Sezer O., Heider U., Jakob C., Zavrski I., Eucker J., Possinger K., Sers C., Krenn V., Giuilani N., Bataiile R., Mancini C., Lazzaretti M., Barlile S., Immunocytochemistry reveals RANKL expression of myeloma cells. Blood 2002 99 12 4646 4647 2-s2.0-0037097587 10.1182/blood-2002-01-0148
43. Croucher P. I., Shipman C. M., Lippitt J., Perry M., Asosingh K., Hijzen A., Brabbs A. C., Van Beek E. J. R., Holen I., Skerry T. M., Dunstan C. R., Russell G. R., Van Camp B., Vanderkerken K., Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001 98 13 3534 3540 2-s2.0-0035895055 10.1182/blood.V98.13.3534
44. Colucci S., Brunetti G., Rizzi R., Zonno A., Mori G., Colaianni G., Del Prete D., Faccio R., Liso A., Capalbo S., Liso V., Zallone A., Grano M., T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood 2004 104 12 3722 3730 2-s2.0-9444231136 10.1182/blood-2004-02-0474
45. Giuliani N., Bataille R., Mancini C., Lazzaretti M., Barillé S., Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001 98 13 3527 3533 2-s2.0-0035895083 10.1182/blood.V98.13.3527
46. Pearse R. N., Sordillo E. M., Yaccoby S., Wong B. R., Liau D. F., Colman N., Michaeli J., Epstein J., Choi Y., Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proceedings of the National Academy of Sciences of the United States of America 2001 98 20 11581 11586 2-s2.0-0035949510 10.1073/pnas. 201394498
47. Roux S., Meignin V., Quillard J., Meduri G., Guiochon-Mantel A., Fermand J., Milgrom E., Mariette X., RANK (receptor activator of nuclear factor- B) and RANKL expression in multiple myeloma. British Journal of Haematology 2002 117 1 86 92 2-s2.0-0036223310 10.1046/j.1365-2141.2002.03417.x
48. Brunetti G., Colucci S., Rizzi R., Mori G., Colaianni G., Oranger A., Zallone A., Liso V., Grano M., The role of OPG/TRAIL complex in multiple myeloma. Annals of the New York Academy of Sciences 2006 1068 1 334 340 2-s2.0-33744745283 10.1196/annals.1346.049
49. Jakob C., Goerke A., Terpos E., Sterz J., Heider U., Kühnhardt D., Ziefle S., Kleeberg L., Mieth M., Metzler I. V., Müller C., Sezer O., Serum levels of total-RANKL in multiple myeloma. Clinical Lymphoma and Myeloma 2009 9 6 430 435 2-s2.0-72549108623 10.3816/CLM.2009.n.085
50. Oshima T., Abe M., Asano J., Myeloma cells suppress osteoblast differentiation by secreting a soluble wnt inhibitor, sFRP-2. Blood 2004 104 2356
51. De Vos J., Couderc G., Tarte K., Jourdan M., Requirand G., Delteil M., Rossi J. F., Mechti N., Klein B., Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood 2001 98 3 771 780 2-s2.0-0035437195 10.1182/blood.V98.3.771
52. Giuliani N., Morandi F., Tagliaferri S., Lazzaretti M., Donofrio G., Bonomini S., Sala R., Mangoni M., Rizzoli V., Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Research 2007 67 16 7665 7674 2-s2.0-34548008809 10.1158/0008-5472.CAN-06-4666
53. Tian E., Zhan F., Walker R., Rasmussen E., Ma Y., Barlogie B., Shaughnessy J. D. Jr., The role of the wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. The New England Journal of Medicine 2003 349 26 2483 2494 2-s2.0-0346363760 10.1056/NEJMoa030847
54. Colucci S., Brunetti G., Oranger A., Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer Journal 2011 1 6, article e27
55. Nusse R., WNT targets: repression and activation. Trends in Genetics 1999 15 1 1 3 2-s2.0-0032916351 10.1016/S0168-9525(98)01634-5
56. Moon R. T., Brown J. D., Torres M., WNTs modulate cell fate and behavior during vertebrate development. Trends in Genetics 1997 13 4 157 162 2-s2.0-0031128225 10.1016/S0168-9525(97)01093-7
57. Gong Y., Slee R. B., Fukai N., LDL receptor related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001 107 513 523
58. Cadigan K. M., Nusse R., Wnt signaling: a common theme in animal development. Genes and Development 1997 11 24 3286 3305 2-s2.0-0031456158
59. + pathways. Oncogene 1999 18 55 7860 7872 2-s2.0-0033590172
60. Krishnan V., Bryant H. U., MacDougald O. A., Regulation of bone mass by Wnt signaling. Journal of Clinical Investigation 2006 116 5 1202 1209 2-s2.0-33646433058 10.1172/JCI28551
61. Qiang Y. W., Chen Y., Stephens O., Brown N., Chen B., Epstein J., Barlogie B., Shaughnessy J. D. Jr., Myeloma-derived dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008 112 1 196 207 2-s2.0-47249140444 10.1182/blood-2008-01-132134
62. Brunetti G., Oranger A., Mori G., Specchia G., Rinaldi E., Curci P., Zallone A., Rizzi R., Grano M., Colucci S., Sclerostin is overexpressed by plasma cells from multiple myeloma patients. Annals of the New York Academy of Sciences 2011 1237 1 19 23 2-s2.0-81255210568 10.1111/j.1749-6632.2011.06196.x
63. Terpos E., Christoulas D., Katodritou E., Bratengeier C., Gkotzamanidou M., Michalis E., Delimpasi S., Pouli A., Meletis J., Kastritis E., Zervas K., Dimopoulos M. A., Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy. International Journal of Cancer 2011 131 6 1466 1471 2-s2.0-83755178943 10.1002/ijc.27342
64. Nanes M. S., Tumor necrosis factor- α: molecular and cellular mechanisms in skeletal pathology. Gene 2003 321 1-2 1 15 2-s2.0-0242409906 10.1016/S0378-1119(03)00841-2
65. Kitaura H., Sands M. S., Aya K., Zhou P., Hirayama T., Uthgenannt B., Wei S., Takeshita S., Novack D. V., Silva M. J., Abu-Amer Y., Ross F. P., Teitelbaum S. L., Marrow stromal cells and osteoclast precursors differentially contribute to TNF- α -induced osteoclastogenesis in vivo. Journal of Immunology 2004 173 8 4838 4846 2-s2.0-6344293669
66. Hideshima T., Chauhan D., Podar K., Schlossman R. L., Richardson P., Anderson K. C., Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Seminars in Oncology 2001 28 6 607 612 2-s2.0-0035211881
67. Ghali O., Chauveau C., Hardouin P., Broux O., Devedjian J., TNF- α 's effects on proliferation and apoptosis in human mesenchymal stem cells depend on RUNX2 expression. Journal of Bone and Mineral Research 2010 25 7 1616 1626 2-s2.0-77954699441 10.1002/jbmr.52
68. Esteve F., Hong C. S., Huston A., Suppression of mesenchymal stromal cell (MSC) differentiation in multiple myeloma (MM) is restricted to the osteoblast lineage. Blood 2008
69. D'Souza S., Del Prete D., Sammut B., Multiple myeloma cell induction of Gfi-1 in stromal cells suppresses runx2 expression and osteoblast differentiation. Proceedings of the 9th International Meeting on Cancer Induced Bone Disease 2009 Arlington, Va, USA University of Pittsburgh
70. D'Souza S., Del Prete D., Esteve F., Multiple myeloma cell induction of Gfi-1 in stromal cells suppresses osteoblast differentiation in patients with myeloma. Blood 2009 114 742
71. Hideshima T., Bergsagel P. L., Kuehl W. M., Anderson K. C., Advances in biology of multiple myeloma: clinical applications. Blood 2004 104 3 607 618 2-s2.0-3242777803 10.1182/blood-2004-01-0037
72. Uchiyama H., Barut B. A., Mohrbacher A. F., Chauhan D., Anderson K. C., Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993 82 12 3712 3720 2-s2.0-0027133422
73. Gupta D., Treon S. P., Shima Y., Hideshima T., Podar K., Tai Y. T., Lin B., Lentzsch S., Davies F. E., Chauhan D., Schlossman R. L., Richardson P., Ralph P., Wu L., Payvandi F., Muller G., Stirling D. I., Anderson K. C., Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001 15 12 1950 1961 2-s2.0-0035195019
74. Dankbar B., Padró T., Leo R., Feldmann B., Kropff M., Mesters R. M., Serve H., Berdel W. E., Kienast J., Vascular endothelial growth factor and interleukin-6 in paracrine tumor- stromal cell interactions in multiple myeloma. Blood 2000 95 8 2630 2636 2-s2.0-0034655957
75. Lowik C. W. G. M., Van Der Pluijm G., Bloys H., Hoekman K., Bijvoet O. L. M., Aarden L. A., Papapoulos S. E., Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochemical and Biophysical Research Communications 1989 162 3 1546 1552 2-s2.0-0024404268
76. Tai Y. T., Li X. F., Breitkreutz I., Song W., Neri P., Catley L., Podar K., Hideshima T., Chauhan D., Raje N., Schlossman R., Richardson P., Munshi N. C., Anderson K. C., Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Research 2006 66 13 6675 6682 2-s2.0-33746122751 10.1158/0008-5472.CAN-06-0190
77. Neri P., Kumar S., Fulciniti M. T., Vallet S., Chhetri S., Mukherjee S., Tai Y., Chauhan D., Tassone P., Venuta S., Munshi N. C., Hideshima T., Anderson K. C., Raje N., Neutralizing B-cell-activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clinical Cancer Research 2007 13 19 5903 5909 2-s2.0-35348915408 10.1158/1078-0432.CCR-07-0753
78. Moreaux J., Legouffe E., Jourdan E., Quittet P., Rème T., Lugagne C., Moine P., Rossi J., Klein B., Tarte K., BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004 103 8 3148 3157 2-s2.0-11144355586 10.1182/blood-2003-06-1984
79. Hemingway F., Taylor R., Knowles H. J., Athanasou N. A., RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II. Bone 2011 48 4 938 944 2-s2.0-79952699649 10.1016/j.bone.2010.12.023
80. Vallet S., Mukherjee S., Vaghela N., Hideshima T., Fulciniti M., Pozzi S., Santo L., Cirstea D., Patel K., Sohani A. R., Guimaraes A., Xie W., Chauhan D., Schoonmaker J. A., Attar E., Churchill M., Weller E., Munshi N., Seehra J. S., Weissleder R., Anderson K. C., Scadden D. T., Raje N., Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proceedings of the National Academy of Sciences of the United States of America 2010 107 11 5124 5129 2-s2.0-77950438331 10.1073/pnas.0911929107
81. Terpos E., Kastritis E., Christoulas D., Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. Annals of Oncology 2012 23 10 2681 2686
82. Terpos E., Politou M., Szydlo R., Goldman J. M., Apperley J. F., Rahemtulla A., Serum levels of macrophage inflammatory protein-1 alpha (MIP-1 α) correlate with the extent of bone disease and survival in patients with multiple myeloma. British Journal of Haematology 2003 123 1 106 109 2-s2.0-0141707692 10.1046/j.1365-2141.2003.04561.x
83. Karadag A., Oyajobi B. O., Apperley J. F., Graham R., Russell G., Croucher P. I., Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts. British Journal of Haematology 2000 108 2 383 390 2-s2.0-0034012201 10.1046/j.1365-2141.2000.01845.x
84. Shipman C. M., Croucher P. I., Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Research 2003 63 5 912 916 2-s2.0-0037374460
85. Yaccoby S., Ling W., Zhan F., Walker R., Barlogie B., Shaughnessy J. D. Jr., Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007 109 5 2106 2111 2-s2.0-33847397091 10.1182/blood-2006-09-047712
86. Edwards C. M., Edwards J. R., Lwin S. T., Esparza J., Oyajobi B. O., McCluskey B., Munoz S., Grubbs B., Mundy G. R., Increasing wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 2008 111 5 2833 2842 2-s2.0-41949093576 10.1182/blood-2007-03-077685
87. Fulciniti M., Tassone P., Hideshima T., Vallet S., Nanjappa P., Ettenberg S. A., Shen Z., Patel N., Tai Y., Chauhan D., Mitsiades C., Prabhala R., Raje N., Anderson K. C., Stover D. R., Munshi N. C., Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009 114 2 371 379 2-s2.0-67650431302 10.1182/blood-2008-11-191577
88. Giuliani N., Ferretti M., Bolzoni M., Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. Leukemia 2012 26 6 1391 1401
89. Teitelbaum S. L., Postmenopausal osteoporosis, T cells, and immune dysfunction. Proceedings of the National Academy of Sciences of the United States of America 2004 101 48 16711 16712 2-s2.0-10044225587 10.1073/pnas.0407335101
90. Rifas L., Arackal S., T cells regulate the expression of matrix metalloproteinase in human osteoblasts via a dual mitogen-activated protein kinase mechanism. Arthritis and Rheumatism 2003 48 4 993 1001 2-s2.0-0037388342 10.1002/art.10872
91. Kay N., Leong T., Kyle R. A., Greipp P., Van Ness B., Bone N., Oken M. M., Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myeloma patients, a study of the Eastern Cooperative Oncology Group (E9487). Leukemia and Lymphoma 1999 33 1-2 127 133 2-s2.0-0032970781
92. Mellstedt H., Holm G., Pettersson D., T cells in monoclonal gammopathies. Scandinavian Journal of Haematology 1982 29 1 57 64 2-s2.0-0019968869
93. Tienhaara A., Pelliniemi T., Peripheral blood lymphocyte subsets in multiple myeloma and monoclonal gammopathy of undetermined significance. Clinical and Laboratory Haematology 1994 16 3 213 223 2-s2.0-0028136913
94. Joshua D. E., Brown R. D., Ho P. J., Gibson J., Regulatory T cells and multiple myeloma. Clinical Lymphoma and Myeloma 2008 8 5 283 286 2-s2.0-58149327333 10.3816/CLM.2008.n.039
95. Peng L., Kjaergäard J., Plautz G. E., Awad M., Drazba J. A., Shu S., Cohen P. A., Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy. Journal of Immunology 2002 169 9 4811 4821 2-s2.0-0036839149
96. Zhou G., Levitsky H. I., Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. Journal of Immunology 2007 178 4 2155 2162 2-s2.0-33846913897
97. Curiel T. J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J. R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M. L., Knutson K. L., Chen L., Zou W., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine 2004 10 9 942 949 2-s2.0-4644237613 10.1038/nm1093
98. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Research 2001 61 12 4766 4772 2-s2.0-0035874949
99. Liyanage U. K., Moore T. T., Joo H., Tanaka Y., Herrmann V., Doherty G., Drebin J. A., Strasberg S. M., Eberlein T. J., Goedegebuure P. S., Linehan D. C., Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. Journal of Immunology 2002 169 5 2756 2761 2-s2.0-0036721629
100. + regulatory T cells in patients with multiple myeloma. Blood 2006 107 10 3940 3949 2-s2.0-33646575622 10.1182/blood-2005-09-3671
101. -/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scandinavian Journal of Immunology 2010 72 6 540 547 2-s2.0-78149270433 10.1111/j.1365-3083.2010.02463.x
102. + Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. British Journal of Haematology 2009 144 5 686 695 2-s2.0-58849093606 10.1111/j.1365-2141.2008.07530.x
103. Prabhala R. H., Neri P., Bae J. E., Tassone P., Shammas M. A., Allam C. K., Daley J. F., Chauhan D., Blanchard E., Thatte H. S., Anderson K. C., Munshi N. C., Dysfunctional T regulatory cells in multiple myeloma. Blood 2006 107 1 301 304 2-s2.0-30144444962 10.1182/blood-2005-08-3101
104. Dhodapkar K. M., Barbuto S., Matthews P., Kukreja A., Mazumder A., Vesole D., Jagannath S., Dhodapkar M. V., Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood 2008 112 7 2878 2885 2-s2.0-53449089919 10.1182/blood-2008-03-143222
105. Prabhala R. H., Pelluru D., Fulciniti M., Prabhala H. K., Nanjappa P., Song W., Pai C., Amin S., Tai Y., Richardson P. G., Ghobrial I. M., Treon S. P., Daley J. F., Anderson K. C., Kutok J. L., Munshi N. C., Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010 115 26 5385 5392 2-s2.0-77955862810 10.1182/blood-2009-10-246660
106. Noonan K., Marchionni L., Anderson J., Pardoll D., Roodman G. D., Borrello I., A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 2010 116 18 3554 3563 2-s2.0-78149322663 10.1182/blood-2010-05-283895
107. Giuliani N., Morandi F., Tagliaferri S., Colla S., Bonomini S., Sammarelli G., Rizzoli V., Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients. Blood 2006 107 2 841 842 2-s2.0-30444432403 10.1182/blood-2005-07-2719
108. Colucci S., Brunetti G., Grano M., Immunoregulation of osteoclast differentiation in multiple myeloma bone disease. Bone Cancer: Progression and Therapeutic Approaches 2010 chapter 6 Elsevier 67 75. Section II: Bone Microenvironment and Bone Cancer
109. Giuliani N., Colla S., Sala R., Moroni M., Lazzaretti M., La Monica S., Bonomini S., Hojden M., Sammarelli G., Barillè S., Bataille R., Rizzoli V., Human myeloma cells stimulate the receptor activator of nuclear factor- B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 2002 100 13 4615 4621 2-s2.0-0037114636 10.1182/blood-2002-04- 1121
110. Iwata M., Graf L., Awaya N., Torok-Storb B., Functional interleukin-7 receptors (IL-7Rs) are expressed by marrow stromal cells: binding of IL-7 increases levels of IL-6 mRNA and secreted protein. Blood 2002 100 4 1318 1325 2-s2.0-0037103193 10.1182/blood-2002-01-0062
111. Giuliani N., Colla S., Morandi F., Lazzaretti M., Sala R., Bonomini S., Grano M., Colucci S., Svaldi M., Rizzoli V., Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005 106 7 2472 2483 2-s2.0-23744498205 10.1182/blood-2004-12-4986
112. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y., Pulendran B., Palucka K., Immunobiology of dendritic cells. Annual Review of Immunology 2000 18 767 811 2-s2.0-0034041033 10.1146/annurev.immunol.18.1.767
113. Wang S., Yang J., Qian J., Wezeman M., Kwak L. W., Yi Q., Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood 2006 107 6 2432 2439 2-s2.0-33644757687 10.1182/blood-2005-06-2486
114. Brown R. D., Pope B., Murray A., Esdale W., Sze D. M., Gibson J., Joy Ho P., Hart D., Joshua D., Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor- β 1 and interleukin-10. Blood 2001 98 10 2992 2998 2-s2.0-0035892109 10.1182/blood.V98.10.2992
115. Wang S., Hong S., Yang J., Qian J., Zhang X., Shpall E., Kwak L. W., Yi Q., Optimizing immunotherapy in multiple myeloma: Restoring the function of
116. Ratta M., Fagnoni F., Curti A., Vescovini R., Sansoni P., Oliviero B., Fogli M., Ferri E., Cuna G. R. D., Tura S., Baccarani M., Lemoli R. M., Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002 100 1 230 237 2-s2.0-0036659945 10.1182/blood.V100.1. 230
117. Onishi Y., Fehervari Z., Yamaguchi T., Sakaguchi S., Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proceedings of the National Academy of Sciences of the United States of America 2008 105 29 10113 10118 2-s2.0-48249103057 10.1073/pnas.0711106105
118. Fizazi K., Lipton A., Mariette X., Body J., Rahim Y., Gralow J. R., Gao G., Wu L., Sohn W., Jun S., Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology 2009 27 10 1564 1571 2-s2.0-63749094012 10.1200/JCO.2008.19.2146
119. Body J., Greipp P., Coleman R. E., Facon T., Geurs F., Fermand J., Harousseau J., Lipton A., Mariette X., Williams C. D., Nakanishi A., Holloway D., Martin S. W., Dunstan C. R., Bekker P. J., A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003 97 3 887 892 2-s2.0-0346837985
120. Abe M., Hiura K., Wilde J., Shioyasono A., Moriyama K., Hashimoto T., Kido S., Oshima T., Shibata H., Ozaki S., Inoue D., Matsumoto T., Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004 104 8 2484 2491 2-s2.0-4944230728 10.1182/blood-2003-11-3839
121. Neri P., Kumar S., Fulciniti M. T., Vallet S., Chhetri S., Mukherjee S., Tai Y., Chauhan D., Tassone P., Venuta S., Munshi N. C., Hideshima T., Anderson K. C., Raje N., Neutralizing B-cell-activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clinical Cancer Research 2007 13 19 5903 5909 2-s2.0-35348915408 10.1158/1078-0432.CCR-07-0753
122. Vallet S., Raje N., Ishitsuka K., Hideshima T., Podar K., Chhetri S., Pozzi S., Breitkreutz I., Kiziltepe T., Yasui H., Ocio E. M., Shiraishi N., Jin J., Okawa Y., Ikeda H., Mukherjee S., Vaghela N., Cirstea D., Ladetto M., Boccadoro M., Anderson K. C., MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood 2007 110 10 3744 3752 2-s2.0-36348988548 10.1182/blood-2007- 05-093294
123. Tian E., Zhan F., Walker R., Rasmussen E., Ma Y., Barlogie B., Shaughnessy J. D. Jr., The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. The New England Journal of Medicine 2003 349 26 2483 2494 2-s2.0-0346363760 10.1056/NEJMoa030847
124. Pozzi S., Yan H., Vallet S., Preclinical validation of a novel Dkk-1 neutralizing antibody for the treatment of multiple myeloma related bone disease. Proceedings of the ASBMR 30th Annual Meeting September 2008 Montreal, Canada 12 16
125. Heath D. J., Chantry A. D., Buckle C. H., Coulton L., Shaughnessy J. D., Evans H. R., Snowden J. A., Stover D. R., Vanderkerken K., Croucher P. I., Inhibiting dickkopf-1 (Dkkl) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. Journal of Bone and Mineral Research 2009 24 3 425 436 2-s2.0-61849137831 10.1359/jbmr.081104
126. Pearsall R. S., Canalis E., Cornwall-Brady M., Underwood K. W., Haigis B., Ucran J., Kumar R., Pobre E., Grinberg A., Werner E. D., Glatt V., Stadmeyer L., Smith D., Seehra J., Bouxsein M. L., A soluble activin Type IIA receptor induces bone formation and improves skeletal integrity. Proceedings of the National Academy of Sciences of the United States of America 2008 105 19 7082 7087 2-s2.0-44349141964 10.1073/pnas.0711263105
127. Chantry A. D., Heath D., Mulivor A. W., Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. Journal of Bone and Mineral Research 2010 25 2633 2646